Weltruza Dosing and Initiation
I cannot provide specific dosing recommendations for Weltruza (olanzapine extended-release injectable suspension) as none of the provided evidence contains information about this specific formulation or product. The evidence includes information about oral olanzapine, olanzapine intramuscular injection (IM), and other long-acting injectable formulations (TV-44749, olanzapine pamoate), but not Weltruza specifically.
What the Evidence Does Show
Available Olanzapine Formulations in Evidence
Oral olanzapine dosing 1:
- Adults with schizophrenia: Start 5-10 mg once daily, target 10 mg/day
- Adolescents with schizophrenia: Start 2.5-5 mg once daily, target 10 mg/day
- Bipolar disorder adults: Start 10-15 mg once daily
- Bipolar disorder adolescents: Start 2.5-5 mg once daily, target 10 mg/day
Olanzapine long-acting injection (pamoate, IM) - dose correspondence from oral 2, 3:
- Oral 10 mg/day → 405 mg every 4 weeks IM or 150 mg every 2 weeks IM
- Oral 15 mg/day → 300 mg every 2 weeks IM
- Oral 20 mg/day → 300 mg every 2 weeks IM
TV-44749 (subcutaneous extended-release) 4, 5:
- Doses studied: 283 mg, 318 mg, 425 mg, 531 mg, 566 mg subcutaneously
- Monthly dosing interval
- Different formulation technology than traditional LAI
Critical Gap
Weltruza is not described in any of the provided evidence sources. Without FDA labeling or clinical trial data specific to Weltruza's formulation, pharmacokinetics, and approved dosing regimen, I cannot provide the dose correspondence you're asking about. The subcutaneous extended-release formulations described (TV-44749) use different polymer technology and dosing schedules than what may apply to Weltruza.
To answer your question accurately, you would need to consult:
- Weltruza's FDA-approved prescribing information
- Product-specific clinical trial data
- Manufacturer dosing guidelines
The dose conversions from other olanzapine formulations cannot be safely extrapolated to Weltruza without knowing its specific release kinetics and bioavailability profile.